The aim of the trial was to compare using cost-effectiveness analysis two scheme of chemotherapy in advanced breast cancer as the first line of therapy. METHODS: Patients were randomly assigned to chemotherapy. Arm A: standard scheme CAF (30 pts), and arm B: scheme TAD (23 pts), 126 cycles. Effect was estimated after finishing 6 cycles. RESULTS: CR or PR was seen in 78% of cases (TAD) and 60% of cases (CAF). Stabilization of the process was 13% and 23%, progression of the process was 9% and 17% accordingly. The cost of each cycle is as follows: hospital expenditures, cost of diagnostic and laboratory tests and expenses on medicine. The cost of 6 cycles per patient is 9845 USD (TAD) and 2140 USD (CAF). But high level of effectiveness of this treatment provides repayment that is demonstrated in table: Scheme Average value Value of effective ChT (USD) (USD) Remission Progression TAD 9845 7705 13843 CAF 2140 1214 4207 It is according 4 cycles 7-8 cycles As a result of cost-effectiveness analysis the analysis of clinical decisions was made and decision tree was built. The final calculation of cost/ effectiveness index showed advantages of TAD scheme compared to CAF scheme: Effect Cost/ effectiveness index TAD CAF General effectiveness 0,0006 0,0040 Remission 0,003 0,0137 So, the advantage of the preliminary data of TAD scheme according to rational utilization makes 37% compared to CAF scheme.